Re-Engineering mRNA Production: Circular RNA Virus-Like Particles as a Scalable, Enzyme-Free Alternative to IVT and LNPs
- How to overcome current IVT and LNP-based mRNA production to avoid unnecessary cost, toxicity, and scalability barriers
- Engineering cells to co-produce circular RNA and virus-like particles in a single yeast biofactory system
- Demonstrating world-first circular RNA VLP constructs for dual-antigen delivery in rabies and beyond to diversity disease indication
- How cellular machinery–based RNA production can transform both commercial vaccine pipelines and personalized therapeutics